Revelation Biosciences raises $15.6M in public offering; believes it regains Nasdaq compliance

REVELATION BIOSCIENCES, INC.

Gross proceeds of ~$15.6M from sale of 2.89M shares and pre-funded warrants, plus 6.45M warrants at $5.36 exercise price.
Net proceeds of ~$14.1M to fund REVTx-100 and REVTx-300 development, including Phase 1a/1b studies and manufacturing.
Company believes it now meets Nasdaq's $2.5M stockholders' equity requirement; bid price compliance at 9 of 10 consecutive days.
Officers and directors subject to 90-day lock-up; institutional investors have leak-out limiting sales to 25% of trading volume until April 10.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

REVELATION BIOSCIENCES, INC. entered into Placement Agency Agreement with Roth Capital Partners, LLC valued at gross proceeds of approximately $15.6 million (effective 2023-02-09).

Action: entry
Agreement: underwriting
Counterparty: Roth Capital Partners, LLC
Value: gross proceeds of approximately $15.6 million
Effective: 2023-02-09

Exact text from the filing

On February 9, 2023, Revelation Biosciences, Inc., (the “Company”), entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”)

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

REVELATION BIOSCIENCES, INC. entered into Purchase Agreement with certain purchasers valued at gross proceeds of approximately $15.6 million (effective 2023-02-09).

Action: entry
Agreement: equity purchase
Counterparty: certain purchasers
Value: gross proceeds of approximately $15.6 million
Effective: 2023-02-09

Exact text from the filing

a securities purchase agreement (the “Purchase Agreement”) with certain purchasers for the purchase and sale, in a registered public offering by the Company (the “Public Offering”), of (i) an aggregate of 2,888,600 shares of its common stock

View on SEC.gov

268 material agreements filed in the last 30 days. Browse all material agreements →

REVELATION BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-002652

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.